SUPRIYA · NSE
Supriya Lifescience Limited
₹906.3
+0.63% (+₹5.65)
Prev. close
₹900.65
Volume
1,30,367
Delivery %
42.3%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Satish Waman Wagh
Headquarters
Mumbai
Employees
607
Website
supriyalifescience.comExchange
View on NSE ↗Key stats
Market cap
₹7,248.68 Cr
P/E ratio (TTM)
36.5
Dividend yield
0.11%
EPS (TTM)
₹24.67
Beta (1Y · daily vs NIFTY 50)
0.63
Beta (5Y · monthly vs NIFTY 50)
1.21
Shares float
2.55 Cr
EPS · quarter ended Jun 2026
₹2.99
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹530.05 Cr | ₹460.94 Cr | ₹570.37 Cr | ₹696.49 Cr | ₹827.88 Cr | |
| EBITDA | ₹221.56 Cr | ₹138.39 Cr | ₹183.61 Cr | ₹270.61 Cr | ₹305.08 Cr |
| ₹151.81 Cr | ₹89.86 Cr | ₹119.11 Cr | ₹187.96 Cr | ₹209.12 Cr | |
| Diluted EPS | ₹18.86 | ₹11.16 | ₹14.8 | ₹23.35 | ₹25.98 |
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹820.28 Cr | ₹921.24 Cr | ₹1,112.31 Cr | ₹1,357.11 Cr | |
| — | ₹22.47 Cr | ₹5.49 Cr | ₹5.38 Cr | ₹5.44 Cr | |
| Stockholders' equity | — | ₹699.46 Cr | ₹815.37 Cr | ₹996.76 Cr | ₹1,197.73 Cr |
Total assets, Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹48.80 Cr | ₹63.61 Cr | ₹113.31 Cr | ₹164.68 Cr | ₹185.77 Cr | |
| Investing cash flow | ₹-59.82 Cr | ₹-123.65 Cr | ₹-173.58 Cr | ₹-152.25 Cr | ₹-176.17 Cr |
| ₹149.65 Cr | ₹-10.28 Cr | ₹-22.36 Cr | ₹-8.23 Cr | ₹-9.88 Cr | |
| Capital expenditure | ₹-59.90 Cr | ₹-108.40 Cr | ₹-145.66 Cr | ₹-162.38 Cr | ₹-152.24 Cr |
| End cash position | — | ₹157.63 Cr | ₹74.96 Cr | ₹79.15 Cr | ₹78.87 Cr |
End cash position has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 21–Dec 22(6Q) | Mar 23 | Jun 23–Jun 26(13Q) |
|---|---|---|---|
| Promoter | 68.24% | 68.28% | 68.30% |
| Public | 31.76% | 31.72% | 31.70% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Supriya Lifescience Limited | ₹7,248.68 Cr | ₹906.3 | 36.5 | 6.05 | 17.5% | 0.00 | +18.1% | +31.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
11 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Supriya Lifescience share price jumps 7%: CDMO, FY27 outlook
Supriya Lifescience shares rose 6.81% to ₹910.90 on Monday. The increase followed positive management guidance for FY27 and the company's strategic repositioning within the pharmaceutical value chain. This places the stock about 16% below its 52-week high.
Supriya Lifescience: FY26 Annual Report & AGM Notice
Supriya Lifescience Limited released its Annual Report for the Financial Year 2025-26. The company also issued a notice for its 18th Annual General Meeting, scheduled for September 24, 2026, at 3:00 PM IST via video conferencing. The report and notice are available on the company's website and stock exchange platforms.